更新
6月18日 - ** 药物开发商Scholar Rock Holding Corp SRRK.O股价上涨17.7%，创下36.68美元的三个月新高
** 如果涨势保持，该股将创下自2024年11月以来的最佳表现
** 该公司称，在一项中期试验中，其实验性药物与礼来公司LLY.N的减肥治疗药物Zepbound联合使用，有助于 (link) 肥胖症患者保持瘦体重
** 在24周的时间里，接受co's药物apitegromab和LLY药物治疗的患者的瘦体重保持率为54.9%，而单独接受Zepbound治疗的患者的瘦体重保持率为54.9%。
** 与单独服用 LLY 的替唑帕肽的患者相比，联合用药的患者减少的脂肪量更多
** 截至上一交易日收盘，股价年累计下跌约 28
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.